ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$INCY:NASDAQ · INCYTE CORP

Sector: health

Conviction from: NASDAQS&P

52-week range: 89.25132.60

A biopharmaceutical company that discovers, develops and commercializes therapies in oncology and dermatology, with lead products including the JAK inhibitor Jakafi.

3 tracked filer(s) hold this · 1 opened, 2 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 53 — mean of 3 scored holder(s) · buyers (new/add) avg 53. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Larry Robbins / Glenview61New buy5,000$606,7500.0%
Bridgewater55Added +21%203,799$24,731,0090.1%
Ancora42Added +18%296$35,9200.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

FiledFormActivist% of classConviction
2026-05-11SCHEDULE 13D/ABAKER BROS. ADVISORS LP15.6%Highfiling
2026-02-10SCHEDULE 13D/ABAKER BROS. ADVISORS LP15.7%Highfiling

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.